Getagraph.com logo
NASDAQ Composite: ( -0.01%) 16 735
S&P 500
(0.80%) 5 277.51 points
Dow Jones
(1.51%) 38 686 points
Nasdaq
(-0.01%) 16 735 points
Oil
(-0.94%) $77.18
Gas
(0.35%) $2.58
Gold
(-0.79%) $2 347.70
Silver
(-3.10%) $30.56
Platinum
(0.63%) $1 044.50
USD/EUR
(-0.17%) $0.921
USD/NOK
(-0.49%) $10.49
USD/GBP
(-0.05%) $0.785
USD/RUB
(0.15%) $90.40

Realtime updates for Supernus Pharmaceuticals [SUPN]

Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturersā€”Specialty & Generic
BUY
66.67%
return 2.21%
SELL
33.33%
return 3.32%
Last Updated31 May 2024 @ 16:00
25% discount on Stockinvest.us - Use code: Podcast

2.07% $ 27.12

SELL 154999 min ago

@ $27.40

Issued: 14 Feb 2024 @ 09:30

Return: -1.02%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -0.36 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States...

Stats
Today's Volume 509 436
Average Volume 472 484
Market Cap 1.49B
EPS $0 ( 2024-05-14 )
Next earnings date ( $0 ) 2024-08-06
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -93.52
ATR14 $0.0300 (0.11%)
Insider Trading
Date Person Action Amount type
2024-03-21 Bhatt Padmanabh P. Buy 14 491 Common Stock
2024-03-21 Bhatt Padmanabh P. Sell 14 491 Employee Stock Option (Right to Buy)
2024-03-21 Bhatt Padmanabh P. Sell 14 491 Common Stock
2024-03-20 Bhatt Padmanabh P. Sell 400 Employee Stock Option (Right to Buy)
2024-03-20 Bhatt Padmanabh P. Buy 400 Common Stock
INSIDER POWER
38.22
Last 100 transactions
Buy: 802 366 | Sell: 356 762

Volume Correlation

Long: 0.13 (neutral)
Short: 0.16 (neutral)
Signal:(62.176) Neutral

Supernus Pharmaceuticals Correlation

10 Most Positive Correlations
ORGS0.887
VTYX0.868
CRTD0.863
XRTX0.863
SOUN0.859
BRKR0.857
LNW0.848
ARQQ0.846
ICLR0.846
BTF0.84
10 Most Negative Correlations
SABR-0.835

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Supernus Pharmaceuticals Correlation - Currency/Commodity

The country flag 0.30
( neutral )
The country flag 0.40
( neutral )
The country flag 0.00
( neutral )
The country flag -0.17
( neutral )
The country flag 0.12
( neutral )
The country flag -0.28
( neutral )

Supernus Pharmaceuticals Financials

Annual 2023
Revenue: $607.52M
Gross Profit: $438.88M (72.24 %)
EPS: $0.0241
FY 2023
Revenue: $607.52M
Gross Profit: $438.88M (72.24 %)
EPS: $0.0241
FY 2022
Revenue: $667.24M
Gross Profit: $580.02M (86.93 %)
EPS: $1.130
FY 2021
Revenue: $579.78M
Gross Profit: $504.71M (87.05 %)
EPS: $1.010

Financial Reports:

No articles found.

Supernus Pharmaceuticals Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators

Total Execution Time: 2.2129189968109 seconds
Number of API calls: 2
Number of DB calls: 8